H. Miles Prince, MD, MBBS discusses data for mogamulizumab from MAVORIC vs real-world vorinostat in R/R MF and SS.
H. Miles Prince, MD, MBBS
Advertisement
H. Miles Prince, MD, MBBS, is an adjunct professor in the School of translational medicine at Monash University, professor and director of Cancer Immunology and Molecular Oncology at Epworth Healthcare, and a hematologist at the Peter MacCallum Cancer Center.
Articles by H. Miles Prince, MD, MBBS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ST-001 nanoFenretinide Shows Antitumor Activity in Previously Treated Cutaneous T-Cell Lymphoma
2
Immune and Single-Cell Profiling Reveals Drivers of Mogamulizumab Resistance in Mycosis Fungoides and Sézary Syndrome
3
Dibotatug Is Safe and Shows Activity in R/R Cytotoxic T/NK Cell Lymphomas
4
CHMP Recommends Pirtobrutinib for EU Approval in CLL Across All Lines of Therapy
5